F
Biocept, Inc.
BIOCQ
$0.00
$0.000.00%
E
Sell
9/29/2023Downgrade
Biocept, Inc. (BIOC) was downgraded to E from E+ on 9/29/2023 due to a decline in the volatility index and valuation index.
Biocept, Inc. (BIOC) was downgraded to E from E+ on 9/29/2023 due to a decline in the volatility index and valuation index.
E
Sell
9/14/2023Upgraded
Biocept, Inc. (BIOC) was upgraded to E+ from E on 9/14/2023 due to an increase in the volatility index.
Biocept, Inc. (BIOC) was upgraded to E+ from E on 9/14/2023 due to an increase in the volatility index.
E
Sell
8/9/2023Downgrade
Biocept, Inc. (BIOC) was downgraded to E from E+ on 8/9/2023 due to a decline in the volatility index and growth index.
Biocept, Inc. (BIOC) was downgraded to E from E+ on 8/9/2023 due to a decline in the volatility index and growth index.
E
Sell
7/25/2023Upgraded
Biocept, Inc. (BIOC) was upgraded to E+ from E on 7/25/2023 due to an increase in the volatility index.
Biocept, Inc. (BIOC) was upgraded to E+ from E on 7/25/2023 due to an increase in the volatility index.
E
Sell
7/10/2023Downgrade
Biocept, Inc. (BIOC) was downgraded to E from E+ on 7/10/2023 due to a decline in the solvency index, volatility index and total return index. Debt to equity increased from 0.2 to 0.64, and the quick ratio declined from 2.73 to 1.8.
Biocept, Inc. (BIOC) was downgraded to E from E+ on 7/10/2023 due to a decline in the solvency index, volatility index and total return index. Debt to equity increased from 0.2 to 0.64, and the quick ratio declined from 2.73 to 1.8.
E
Sell
3/14/2023Downgrade
Biocept, Inc. (BIOC) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index.
Biocept, Inc. (BIOC) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index.
D
Sell
2/23/2023Upgraded
Biocept, Inc. (BIOC) was upgraded to D- from E+ on 2/23/2023 due to an increase in the volatility index.
Biocept, Inc. (BIOC) was upgraded to D- from E+ on 2/23/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
Biocept, Inc. (BIOC) was downgraded to E+ from D- on 2/8/2023 due to a decline in the growth index, solvency index and volatility index. Total revenue declined 47.35% from $10.61M to $5.59M, debt to equity increased from 0.06 to 0.07, and EBIT declined 9.42% from -$5.1M to -$5.58M.
Biocept, Inc. (BIOC) was downgraded to E+ from D- on 2/8/2023 due to a decline in the growth index, solvency index and volatility index. Total revenue declined 47.35% from $10.61M to $5.59M, debt to equity increased from 0.06 to 0.07, and EBIT declined 9.42% from -$5.1M to -$5.58M.
D
Sell
11/16/2022Downgrade
Biocept, Inc. (BIOC) was downgraded to D- from D on 11/16/2022 due to a significant decline in the growth index, total return index and volatility index. Operating cash flow declined 333.48% from -$932 to -$4.04M, earnings per share declined from -$0.1643 to -$0.3107, and EBIT declined 88.29% from -$2.71M to -$5.1M.
Biocept, Inc. (BIOC) was downgraded to D- from D on 11/16/2022 due to a significant decline in the growth index, total return index and volatility index. Operating cash flow declined 333.48% from -$932 to -$4.04M, earnings per share declined from -$0.1643 to -$0.3107, and EBIT declined 88.29% from -$2.71M to -$5.1M.
D
Sell
5/25/2022Upgraded
Biocept, Inc. (BIOC) was upgraded to D from D- on 5/25/2022 due to a significant increase in the growth index and valuation index. Total revenue increased 42.71% from $13.98M to $19.95M, earnings per share increased from -$0.1765 to -$0.1643, and EBIT increased 2.47% from -$2.78M to -$2.71M.
Biocept, Inc. (BIOC) was upgraded to D from D- on 5/25/2022 due to a significant increase in the growth index and valuation index. Total revenue increased 42.71% from $13.98M to $19.95M, earnings per share increased from -$0.1765 to -$0.1643, and EBIT increased 2.47% from -$2.78M to -$2.71M.
D
Sell
5/5/2022Upgraded
Biocept, Inc. (BIOC) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index.
Biocept, Inc. (BIOC) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index.
E
Sell
4/20/2022Downgrade
Biocept, Inc. (BIOC) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index and volatility index.
Biocept, Inc. (BIOC) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index and volatility index.
D
Sell
4/18/2022Downgrade
Biocept, Inc. (BIOC) was downgraded to D- from D+ on 4/18/2022 due to a significant decline in the efficiency index, valuation index and growth index. EBIT declined 404.45% from -$550.2 to -$2.78M, net income declined 375.6% from -$624.7 to -$2.97M, and earnings per share declined from -$0.0406 to -$0.1765.
Biocept, Inc. (BIOC) was downgraded to D- from D+ on 4/18/2022 due to a significant decline in the efficiency index, valuation index and growth index. EBIT declined 404.45% from -$550.2 to -$2.78M, net income declined 375.6% from -$624.7 to -$2.97M, and earnings per share declined from -$0.0406 to -$0.1765.
D
Sell
11/16/2021Upgraded
Biocept, Inc. (BIOC) was upgraded to D+ from D- on 11/16/2021 due to a significant increase in the efficiency index, valuation index and growth index. Total revenue increased 190.02% from $12.05M to $34.94M, EBIT increased 157.39% from -$1.75M to $1M, and total capital increased 149.34% from $42.49M to $105.94M.
Biocept, Inc. (BIOC) was upgraded to D+ from D- on 11/16/2021 due to a significant increase in the efficiency index, valuation index and growth index. Total revenue increased 190.02% from $12.05M to $34.94M, EBIT increased 157.39% from -$1.75M to $1M, and total capital increased 149.34% from $42.49M to $105.94M.
D
Sell
11/8/2021Downgrade
Biocept, Inc. (BIOC) was downgraded to D- from D on 11/8/2021 due to a major decline in the growth index and valuation index. Earnings per share declined from $0.19 to -$0.14, EBIT declined 165.6% from $2.66M to -$1.75M, and total revenue declined 32.15% from $17.76M to $12.05M.
Biocept, Inc. (BIOC) was downgraded to D- from D on 11/8/2021 due to a major decline in the growth index and valuation index. Earnings per share declined from $0.19 to -$0.14, EBIT declined 165.6% from $2.66M to -$1.75M, and total revenue declined 32.15% from $17.76M to $12.05M.
D
Sell
3/30/2020Upgraded
Biocept, Inc. (BIOC) was upgraded to D from E+ on 3/30/2020 due to a noticeable increase in the growth index and solvency index. Debt to equity declined from 0.27 to 0.14, the quick ratio increased from 1.63 to 2.31, and earnings per share increased from -$0.25 to -$0.1969.
Biocept, Inc. (BIOC) was upgraded to D from E+ on 3/30/2020 due to a noticeable increase in the growth index and solvency index. Debt to equity declined from 0.27 to 0.14, the quick ratio increased from 1.63 to 2.31, and earnings per share increased from -$0.25 to -$0.1969.
E
Sell
8/20/2019Downgrade
Biocept, Inc. (BIOC) was downgraded to E+ from D- on 8/20/2019 due to a decline in the growth index and efficiency index. Net income declined 32.1% from -$5.92M to -$7.82M, operating cash flow declined 28.11% from -$5.25M to -$6.72M, and total capital declined 6.28% from $17.49M to $16.39M.
Biocept, Inc. (BIOC) was downgraded to E+ from D- on 8/20/2019 due to a decline in the growth index and efficiency index. Net income declined 32.1% from -$5.92M to -$7.82M, operating cash flow declined 28.11% from -$5.25M to -$6.72M, and total capital declined 6.28% from $17.49M to $16.39M.
D
Sell
5/28/2019Downgrade
Biocept, Inc. (BIOC) was downgraded to D- from D on 5/28/2019 due to a decline in the total return index.
Biocept, Inc. (BIOC) was downgraded to D- from D on 5/28/2019 due to a decline in the total return index.
D
Sell
3/29/2019Upgraded
Biocept, Inc. (BIOC) was upgraded to D from D- on 3/29/2019 due to an increase in the growth index, solvency index and valuation index. Earnings per share increased from -$2.42 to -$1.4209, total revenue increased 12.85% from $761.6 to $859.5, and EBIT increased 1.16% from -$6.01M to -$5.94M.
Biocept, Inc. (BIOC) was upgraded to D from D- on 3/29/2019 due to an increase in the growth index, solvency index and valuation index. Earnings per share increased from -$2.42 to -$1.4209, total revenue increased 12.85% from $761.6 to $859.5, and EBIT increased 1.16% from -$6.01M to -$5.94M.
D
Sell
8/16/2018Upgraded
Biocept, Inc. (BIOC) was upgraded to D- from E+ on 8/16/2018 due to an increase in the growth index and total return index. Earnings per share increased from -$3.3404 to -$2.7, EBIT increased 3.74% from -$6.27M to -$6.04M, and total revenue increased 1.9% from $806.9 to $822.2.
Biocept, Inc. (BIOC) was upgraded to D- from E+ on 8/16/2018 due to an increase in the growth index and total return index. Earnings per share increased from -$3.3404 to -$2.7, EBIT increased 3.74% from -$6.27M to -$6.04M, and total revenue increased 1.9% from $806.9 to $822.2.
E
Sell
5/16/2018Downgrade
Biocept, Inc. (BIOC) was downgraded to E+ from D- on 5/16/2018 due to a decline in the growth index, volatility index and total return index. Total revenue declined 18.92% from $995.2 to $806.9, and EBIT declined 12.7% from -$5.57M to -$6.27M.
Biocept, Inc. (BIOC) was downgraded to E+ from D- on 5/16/2018 due to a decline in the growth index, volatility index and total return index. Total revenue declined 18.92% from $995.2 to $806.9, and EBIT declined 12.7% from -$5.57M to -$6.27M.
D
Sell
3/29/2018Downgrade
Biocept, Inc. (BIOC) was downgraded to D- from D on 3/29/2018 due to a noticeable decline in the efficiency index, solvency index and valuation index. Debt to equity increased from 0.51 to 1.26, total capital declined 42.03% from $7.05M to $4.09M, and the quick ratio declined from 1.2 to 0.72.
Biocept, Inc. (BIOC) was downgraded to D- from D on 3/29/2018 due to a noticeable decline in the efficiency index, solvency index and valuation index. Debt to equity increased from 0.51 to 1.26, total capital declined 42.03% from $7.05M to $4.09M, and the quick ratio declined from 1.2 to 0.72.
D
Sell
1/30/2018Upgraded
Biocept, Inc. (BIOC) was upgraded to D from D- on 1/30/2018 due to an increase in the efficiency index, growth index and valuation index. Earnings per share increased from -$0.2126 to -$0.2, and operating cash flow increased 4.97% from -$5.21M to -$4.95M.
Biocept, Inc. (BIOC) was upgraded to D from D- on 1/30/2018 due to an increase in the efficiency index, growth index and valuation index. Earnings per share increased from -$0.2126 to -$0.2, and operating cash flow increased 4.97% from -$5.21M to -$4.95M.
D
Sell
5/17/2017Upgraded
Biocept, Inc. (BIOC) was upgraded to D- from E+ on 5/17/2017 due to a major increase in the solvency index, valuation index and efficiency index. Total capital increased 193.97% from $4.83M to $14.21M, the quick ratio increased from 1.08 to 2.73, and debt to equity declined from 5.16 to 0.36.
Biocept, Inc. (BIOC) was upgraded to D- from E+ on 5/17/2017 due to a major increase in the solvency index, valuation index and efficiency index. Total capital increased 193.97% from $4.83M to $14.21M, the quick ratio increased from 1.08 to 2.73, and debt to equity declined from 5.16 to 0.36.
E
Sell
3/31/2017Downgrade
Biocept, Inc. (BIOC) was downgraded to E+ from D+ on 3/31/2017 due to a significant decline in the efficiency index, solvency index and valuation index. Debt to equity increased from -0.83 to 5.16.
Biocept, Inc. (BIOC) was downgraded to E+ from D+ on 3/31/2017 due to a significant decline in the efficiency index, solvency index and valuation index. Debt to equity increased from -0.83 to 5.16.
D
Sell
3/7/2017Upgraded
Biocept, Inc. (BIOC) was upgraded to D+ from D on 3/7/2017 due to an increase in the volatility index and total return index.
Biocept, Inc. (BIOC) was upgraded to D+ from D on 3/7/2017 due to an increase in the volatility index and total return index.
D
Sell
11/18/2016Upgraded
Biocept, Inc. (BIOC) was upgraded to D from D- on 11/18/2016 due to a significant increase in the efficiency index and valuation index.
Biocept, Inc. (BIOC) was upgraded to D from D- on 11/18/2016 due to a significant increase in the efficiency index and valuation index.
D
Sell
3/11/2016Downgrade
Biocept, Inc. (BIOC) was downgraded to D- from D on 3/11/2016 due to a major decline in the volatility index, total return index and valuation index.
Biocept, Inc. (BIOC) was downgraded to D- from D on 3/11/2016 due to a major decline in the volatility index, total return index and valuation index.
D
Sell
1/15/2016Downgrade
Biocept, Inc. (BIOC) was downgraded to D from D+ on 1/15/2016 due to a noticeable decline in the total return index.
Biocept, Inc. (BIOC) was downgraded to D from D+ on 1/15/2016 due to a noticeable decline in the total return index.
D
Sell
12/31/2015Upgraded
Biocept, Inc. (BIOC) was upgraded to D+ from D on 12/31/2015 due to a large increase in the total return index, efficiency index and growth index. Total revenue increased 114.71% from $76.8 to $164.9, EBIT increased 12.03% from -$3.89M to -$4.36M, and net income increased 11.43% from -$4.04M to -$4.5M.
Biocept, Inc. (BIOC) was upgraded to D+ from D on 12/31/2015 due to a large increase in the total return index, efficiency index and growth index. Total revenue increased 114.71% from $76.8 to $164.9, EBIT increased 12.03% from -$3.89M to -$4.36M, and net income increased 11.43% from -$4.04M to -$4.5M.
D
Sell
3/2/2015Upgraded
Biocept, Inc. (BIOCQ) was upgraded to D from D- on 03/02/2015.
Biocept, Inc. (BIOCQ) was upgraded to D from D- on 03/02/2015.
D
Sell
11/3/2014Upgraded
Biocept, Inc. (BIOCQ) was upgraded to D- from E+ on 11/03/2014.
Biocept, Inc. (BIOCQ) was upgraded to D- from E+ on 11/03/2014.
E
Sell
8/1/2014Upgraded
Biocept, Inc. (BIOC) was upgraded to E+ from E on 8/1/2014 due to a substantial increase in the solvency index and total return index. The quick ratio increased from 0.01 to 7.15, and debt to equity declined from -0.59 to 0.
Biocept, Inc. (BIOC) was upgraded to E+ from E on 8/1/2014 due to a substantial increase in the solvency index and total return index. The quick ratio increased from 0.01 to 7.15, and debt to equity declined from -0.59 to 0.
E
Sell
5/1/2014Upgraded
Biocept, Inc. (BIOC) was upgraded to E from on 5/1/2014 due to a significant increase in the growth index, efficiency index and solvency index. Total capital increased 157.84% from -$1.96M to -$5.06M.
Biocept, Inc. (BIOC) was upgraded to E from on 5/1/2014 due to a significant increase in the growth index, efficiency index and solvency index. Total capital increased 157.84% from -$1.96M to -$5.06M.
OTC PK
03/05/2025 10:22AM Eastern
Quotes delayed
